1																2
3														4
												5
															6											7
								8
9
																							10
							11
12
			13						14												15
											16
		17
														18
		19

Across 3. The modification of nociceptive transmission. 4. Conduction of pain impulses from peripheral pain receptors to the spinal cord. 6. Caused by the physician (veterinarian). 8. Hyperadrenocorticism; a disease or syndrome characterized by an overabundance of corticosteroid hormones. 9. The use of different drugs with different actions to produce optimal analgesia and minimize individual drug quantities when possible. 11. A loss of feeling or sensation produced by injecting an anesthetic agent around a nerve to interfere with its ability to conduct impulses. 12. Analgesia administered before the painful stimulus to help prevent sensitization and windup. 14. The protective sensation of pain that allows the individual to move away from potential tissue damage. 16. Pain that originates from injury or involvement of the peripheral or central nervous system. 17. A disease or syndrome characterized by inadequate amounts of corticosteroid hormones. 18. A chemical mediator of the inflammatory response released from mast cells. _________ may cause a dilation and increased permeability of small blood vessels, constriction of small airways, increased secretion of mucus in airways, and pain. 19. The absence of the sensation of pain.

Down 1. The use of a patch applied to the skin to deliver a drug through an intact cutaneous surface to the systemic circulation. 2. Pain arising from stretching, distension, or inflammation of viscera. ________ is described in humans as deep, cramping, or aching and difficult to localize. 5. Loss of feeling or sensation in a large area of the body after injection of an anesthetic agent into the spinal canal or around peripheral nerves. 7. Pain with an exaggerated response; it is often associated with tissue injury due to trauma or surgery. 10. Pain arising from bones, joints, muscle or skin. _________ is described in humans as localized, sharp, constant, achine, or throbbing. 12. A substance synthesized by cells from arachidonic acid that serves as a mediator of inflammation and has other physiologic functions. 13. The process that involves translation of noxious stimuli into electric activity at sensory nerve endings. 15. The processing and recognition of pain in the cerebral hemispheres.